دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection
Jessica R Allegretti, MD, MPH, Colleen R Kelly, MD, Ari Grinspan, MD, Benjamin H Mullish, PhD, Jonathan Hurtado, Madeline Carrellas, Jenna Marcus, Julian R Marchesi, PhD, Julie A K McDonald, PhD, Ylaine Gerardin, PhD, Michael Silverstein, PhD, Alexandros Pechlivanis, PhD, Grace F Barker, MPhil, Jesus Miguens Blanco, MPhil, James L Alexander, PhD, Kate I Gallagher, MPhil, Will Pettee, Emmalee Phelps, Sara Nemes, Sashidhar V Sagi, MD, Matthew Bohm, MD, Zain Kassam, MD, MPH, Monika Fischer, MD, MSc
doi : 10.1093/ibd/izaa283
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1371–1378
Recurrent Clostridioides difficile infection (CDI) in patients with inflammatory bowel disease (IBD) is a clinical challenge. Fecal microbiota transplantation (FMT) has emerged as a recurrent CDI therapy. Anecdotal concerns exist regarding worsening of IBD activity; however, prospective data among IBD patients are limited.
Ac2-26-Nanoparticles Induce Resolution of Intestinal Inflammation and Anastomotic Healing via Inhibition of NF-?B Signaling in a Model of Perioperative Colitis
Stefan Reischl, MD, Jong Hyun Lee, PhD, Joseph Raphael Elias Miltschitzky, Vincent Vieregge, Robert Leon Walter, Vanessa Twardy, MD, Atsuko Kasajima, MD, Helmut Friess, MD, Nazila Kamaly, PhD, Philipp-Alexander Neumann, MD
doi : 10.1093/ibd/izab008
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1379–1393
Although in most patients with inflammatory bowel diseases, conservative therapy is successful, a significant proportion of patients still require surgery once in their lifetime. Development of a safe perioperative treatment to dampen colitis activity without disturbance of anastomotic healing is an urgent and unmet medical need. Annexin A1 (ANXA1) has been shown to be effective in reducing colitis activity. Herein, a nanoparticle-based perioperative treatment approach was used for analysis of the effects of ANXA1 on the resolution of inflammation after surgery for colitis.
Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
Jeffrey R Curtis, MD, MS, MPH, Miguel Regueiro, MD, Huifeng Yun, PhD, Chinyu Su, MD, Marco DiBonaventura, PhD, Nervin Lawendy, PharmD, Chudy I Nduaka, MD, Nana Koram, PhD, MPH, Joseph C Cappelleri, PhD, MPH, Gary Chan, PharmD, Irene Modesto, MD, PhD, Gary R Lichtenstein, MD
doi : 10.1093/ibd/izaa289
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1394–1408
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We aimed to estimate the overall incidence of safety events in patients with UC in a real-life population cohort for comparison with the tofacitinib UC clinical trial program.
Utilization of an Electronic Medical Record–integrated Dashboard Improves Identification and Treatment of Anemia and Iron Deficiency in Pediatric Inflammatory Bowel Disease
Jessica Breton, MD, Char M Witmer, MD, Yuchen Zhang, ME, Maura Downing, MHA, Jamie Stevenson, RN, Janine McDermott, RN, Shazia M Siddique, MD, Andrew B Grossman, MD
doi : 10.1093/ibd/izaa288
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1409–1417
Iron deficiency (ID) and anemia are one of the most common extraintestinal manifestations of inflammatory bowel disease (IBD), usually complicating the course both in ulcerative colitis and Crohn’s disease. Despite their high prevalence and significant impact on patients, this particular aspect is still underestimated by clinicians. Although guidelines have been recently published to address this problem, these recommendations do not address pediatric specific concerns and do not provide guidance as to how implement these guidelines in clinical practice. The aims of this quality improvement (QI) initiative were to improve the rates of detection and treatment of anemia in children with IBD.
Delivery Outcomes of Pregnant Patients With Inflammatory Bowel Diseases Compared With the General Population and With Women With Other Autoimmune Diseases at a Tertiary Care Center
Taylor Geisman, MD, Ling Chen, MD, PhD, Margaret Rosanna Gray-Swain, MD, Deborah Hiatt-Jensen, MSN, NP-C, MPH, Alexandra Gutierrez, MD, MPH
doi : 10.1093/ibd/izaa290
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1418–1426
Variable data have suggested that pregnant women with inflammatory bowel diseases (IBD) are more likely to have cesarean deliveries and adverse pregnancy outcomes than the general population. The aim of this study was to describe the rates of cesarean delivery and adverse pregnancy outcomes among patients with IBD as compared with patients with other autoimmune diseases and with the general population.
The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing
Gabriella Bröms, MD, PhD, Sonia Friedman, MD, Seoyoung C Kim, MD, ScD, Mollie E Wood, MPH, PhD, Sonia Hernandez-Diaz, MD, DrPH, Gregory Brill, MS, Brian T Bateman, MD, MS, Krista F Huybrechts, MS, PhD, Rishi J Desai, MS, PhD
doi : 10.1093/ibd/izaa294
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1427–1434
Population-level data spanning different countries describing oral and parenteral treatment in pregnant women with inflammatory bowel disease (IBD) are scarce. We studied treatment with sulfasalazine/5-aminosalicylates, corticosteroids, thiopurines/immunomodulators, and tumor necrosis factor (TNF)-inhibitors in the United States (Optum Clinformatics Data Mart and the Medicaid Analytics Extract [MAX]) and in the Swedish national health registers.
Assessment of Body Composition From CT Images at the Level of the Third Lumbar Vertebra in Inflammatory Bowel Disease
Shigeki Bamba, MD, PhD, Osamu Inatomi, MD, PhD, Kenichiro Takahashi, MD, PhD, Yasuhiro Morita, MD, Takayuki Imai, MD, PhD, Masashi Ohno, MD, PhD, Mika Kurihara, RD, Katsushi Takebayashi, MD, PhD, Masatsugu Kojima, MD, PhD, Hiroya Iida, MD, PhD, Masaji Tani, MD, PhD, Masaya Sasaki, MD, PhD
doi : 10.1093/ibd/izaa306
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1435–1442
Although there are several reports of associations between body composition parameters and outcomes in patients with inflammatory bowel disease (IBD), it is not clear which muscle tissue parameters and/or adipose tissue parameters most strongly affect outcomes. Therefore, this study sought to determine the associations of such parameters determined at the level of the third lumbar vertebra (L3) on computed tomography (CT) images with outcomes in IBD patients.
Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease
Robert Battat, MD, Dana Lukin, MD, PhD, Ellen J Scherl, MD, Suresh Pola, MD, Anand Kumar, MD, Lauren Okada, Lei Yang, PhD, Anjali Jain, PhD, Corey A Siegel, MD, MS
doi : 10.1093/ibd/izaa313
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1443–1451
Infliximab and adalimumab concentrations are associated with important outcomes in inflammatory bowel disease (IBD). Antibodies to infliximab (ATI) and adalimumab (ATA) are associated with reduced drug concentrations and worse outcomes. Because the efficacy of dose escalation to overcome antibodies is unclear, we assessed the impact of this strategy to overcome immunogenicity in IBD.
Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment
Sun-Ho Lee, MD, MSc, Margaret Walshe, MD, Eun Hye Oh, MD, MSc, Sung Wook Hwang, MD, PhD, Sang Hyoung Park, MD, PhD, Dong-Hoon Yang, MD, PhD, Jeong-Sik Byeon, MD, PhD, Seung-Jae Myung, MD, PhD, Suk-Kyun Yang, MD, PhD, Tomer Greener, MD, Adam V Weizman, MD, MSc, Mark S Silverberg, MD, PhD, Byong Duk Ye, MD, PhD
doi : 10.1093/ibd/izaa309
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1452–1461
Up to 60% of patients with ulcerative colitis (UC) ultimately fail anti-tumor necrosis factor (TNF) treatment. We aimed to investigate early predictive markers of clinical and endoscopic outcomes in patients with UC who were anti-TNF-naïve commencing anti-TNF treatment, with particular focus on changes in albumin and C-reactive protein levels in the first 2 weeks of treatment.
The Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study
Charles N Bernstein, MD, Carol A Hitchon, MD, MSc, Randy Walld, James M Bolton, MD, Lisa M Lix, PhD, Renée El-Gabalawy, PhD, Jitender Sareen, MD, Alexander Singer, MB, BAO, BCh, Alan Katz, MBChB, MSc, James Marriott, MD, John D Fisk, PhD, Scott B Patten, MD, PhD, Ruth Ann Marrie, MD, PhD
doi : 10.1093/ibd/izaa310
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1462–1474
Inflammatory bowel disease (IBD) is associated with an increase in psychiatric comorbidity (PC) compared with the general population. We aimed to determine the impact of PC on health care utilization in persons with IBD.
Serrated Epithelial Change Is Associated With High Rates of Neoplasia in Ulcerative Colitis Patients: A Case-controlled Study and Systematic Review With Meta-analysis
Alyssa M Parian, MD, Berkeley N Limketkai, MD, PhD, Reezwana Chowdhury, MD, Gala Godoy Brewer, MD, George Salem, MD, Katie Falloon, MD, Florin Selaru, MD, Joanna Melia, MD, Mark G Lazarev, MD
doi : 10.1093/ibd/izaa312
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1475–1481
Patients with long-standing ulcerative colitis (UC) are at an increased risk of colorectal cancer. Risk stratification is important to identify patients who require more frequent endoscopic surveillance. Serrated epithelial change (SEC) found in patients with long-standing colitis may be associated with neoplasia and serve as a marker to stratify patients at higher risk of colorectal cancer (CRC).
Collagenous Colitis Mucosa Is Characterized by an Expansion of Nonsuppressive FoxP3+ T Helper Cells
Niki Daferera, MD, Celia Escudero-Hernández, PHD, PostDoc, Sofia Nyström, MD, PHD, Maria C Jenmalm, PhD, Henrik Hjortswang, MD, Simone Ignatova, MD, PHD, Magnus Ström, MD, Andreas Münch, MD
doi : 10.1093/ibd/izaa322
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1482–1490
Increased frequencies of T regulatory (Treg) cells, key players in immune regulation, have been reported in inflammatory bowel diseases, including collagenous colitis (CC). However, traditional Treg identification techniques might have misinterpreted the frequencies of Treg cells in CC. Thus, we investigated the presence of genuine Treg cells in CC.
Matricellular Protein SPARCL1 Regulates Blood Vessel Integrity and Antagonizes Inflammatory Bowel Disease
Daniela Regensburger, MSc, Clara Tenkerian, PhD, Victoria Pürzer, MSc, Benjamin Schmid, PhD, Thomas Wohlfahrt, PhD, Iris Stolzer, MSc, Rocío López-Posadas, PhD, Claudia Günther, PhD, Maximilian J Waldner, MD, Christoph Becker, PhD, Heinrich Sticht, PhD, Katja Petter, MSc, Christian Flierl, Tobias Gass, Tim Thoenissen, Carol I Geppert, MD, Nathalie Britzen-Laurent, PhD, Valérie S Méniel, PhD, Andreas Ramming, MD, Michael Stürzl, PhD, Elisabeth Naschberger, PhD
doi : 10.1093/ibd/izaa346
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1491–1502
The understanding of vascular plasticity is key to defining the role of blood vessels in physiologic and pathogenic processes. In the present study, the impact of the vascular quiescence marker SPARCL1 on angiogenesis, capillary morphogenesis, and vessel integrity was evaluated.
Ileocolonic Healing After Extended Small Bowel Resection in Mice: NOD2 Deficiency Impairs Anastomotic Healing and Postoperative Outcome
Maria Witte, MD, Johannes Reiner, MD, Karen Bannert, PhD, Robert Jaster, MD, Christian Maschmeier, MSc, Clemens Schafmayer, MD, Georg Lamprecht, MD, Peggy Berlin, PhD
doi : 10.1093/ibd/izab022
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1503–1512
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) mutations are a genetic risk factor for Crohn disease. Ileocecal resection is the most often performed surgery in Crohn disease. We investigated the effect of Nod2 knockout (KO) status on anastomotic healing after extended ileocecal resection (ICR) in mice.
Medical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews
Nilesh Chande, MD, Siddharth Singh, MD, Neeraj Narula, MD, MPH, Morris Gordon, MD, M Ellen Kuenzig, PhD, Tran M Nguyen, MSc, John K MacDonald, MA, Brian G Feagan, MD
doi : 10.1093/ibd/izaa350
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1513–1524
Alterations in Bile Acid Metabolism Associated With Inflammatory Bowel Disease
Na Li, MM, Shukai Zhan, MD, Zhenyi Tian, MD, Caiguang Liu, MM, Zonglin Xie, MM, Shenghong Zhang, MD, Minhu Chen, MD, Zhirong Zeng, MD, Xiaojun Zhuang, MD, PhD
doi : 10.1093/ibd/izaa342
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1525–1540
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder closely related to gut dysbiosis, which is associated with alterations in an important bacterial metabolite, bile acids (BAs). Although certain findings pertinent to BA changes in IBD vary among studies owing to the differences in sample type, quantitated BA species, study methodology, and patient characteristics, a specific trend concerning variations of BAs in IBD has been identified. In elaborating on this observation, it was noted that primary BAs and conjugated BAs are augmented in fecal samples but there is a reduction in secondary BAs in fecal samples. It is not entirely clear why patients with IBD manifest these changes and what role these changes play in the onset and development of IBD. Previous studies have shown that IBD-associated BA changes may be caused by alterations in BA absorption, synthesis, and bacterial modification. The complex relationship between bacteria and BAs may provide additional and deeper insight into host-gut microbiota interactions in the pathogenesis of IBD. The characteristic BA changes may generate profound effects in patients with IBD by shaping the gut microbiota community, affecting inflammatory processes, causing BA malabsorption associated with diarrhea, and even leading to intestinal dysplasia and cancer. Thus, therapeutic strategies correcting the alterations in the composition of BAs, including the elimination of excess BAs and the supplementation of deficient BAs, may prove promising in IBD.
Systematic Review of Inclusion and Analysis of Older Adults in Randomized Controlled Trials of Medications Used to Treat Inflammatory Bowel Diseases
Bharati Kochar, MD, MSCR, Lakshman Kalasapudi, MA, Nneka N Ufere, MD, Ryan D Nipp, MD, MPH, Ashwin N Ananthakrishnan, MD, MPH, Christine S Ritchie, MD, MSPH
doi : 10.1093/ibd/izab052
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1541–1543
The Use of Biologics for the Treatment of Esophageal Crohn Disease
Jacob Lui, Guilherme Piovezani Ramos, MD, Don Chamil Codipilly, MD, David Katzka, MD, Laura E Raffals, MD
doi : 10.1093/ibd/izab070
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1544–1547
Disparity in the Care of Black Inflammatory Bowel Disease Patients
Julia J Liu, MD, MSc
doi : 10.1093/ibd/izab100
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages 1548–1549
Corrigendum to: Fungal Dysbiosis Aggravates Pouchitis in a Rat Model of Ileal Pouch Anal Anastomosis
doi : 10.1093/ibd/izab103
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Page 1550
Risk of Depression During the Natural History of Inflammatory Bowel Disease: The Phantom Menace: Letter in response to: The Relationship Between Symptoms of Depression and Anxiety and Disease Activity in IBD Over Time. Inflamm Bowel Dis. 2021; doi: 10.1093/ibd/izaa349.
Iago Rodríguez-Lago, MD, PhD, Manuel Barreiro-de Acosta, MD, PhD
doi : 10.1093/ibd/izab067
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages e99–e100
Tofacitinib in Acute Severe Ulcerative Colitis: Case Series and a Systematic Review
Anuraag Jena, MD, DM, Shubhra Mishra, MD, Anurag Sachan, MD, Harjeet Singh, MS, M.Ch, Anupam Kumar Singh, MD, DM, Vishal Sharma, MD, DM
doi : 10.1093/ibd/izab087
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages e101–e103
High Fecal Proteolytic Activity That Precedes Ulcerative Colitis Likely Results From Impaired Inactivation of Pancreatic Proteases Rather Than Bacteria
Xiaofa Qin, MD, PhD
doi : 10.1093/ibd/izab142
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Page e104
Combined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative Colitis
Patrick Hilley, MPharm, Robert Gilmore, MBChB, Ashish Srinivasan, MBBS, Matthew Choy, PhD, Peter De Cruz, PhD
doi : 10.1093/ibd/izab095
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages e105–e106
Tofacitinib in Acute Severe Ulcerative Colitis: Case Series and a Systematic Review–Authors’ Reply
Carlos Taxonera, MD, PhD, David Olivares, Cristina Alba, MD
doi : 10.1093/ibd/izab088
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Page e107
IgA-Mediated Warm Autoimmune Hemolytic Anemia as an Extraintestinal Manifestation in a Patient With Crohn Disease on Vedolizumab
Matthew Cheah, MD, FRCPC, Aze Wilson, MD, PhD, FRCPC, Ziad Solh, MD, MSc, FRCPC, Reena Khanna, MD, MSc, FRCPC
doi : 10.1093/ibd/izab090
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages e108–e109
Pyoderma Gangrenosum in An Ulcerative Colitis Pediatric Patient During Vedolizumab Therapy Successfully Treated With Oral Cyclosporine
Francesco Graziano, MD, Fabio Salvatore Macaluso, MD, Nicola Cassata, MD, Michele Citrano, MD, Ambrogio Orlando, MD
doi : 10.1093/ibd/izab106
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages e110–e111
Crohn-Like Colitis in a Young Boy With Hirschsprung Disease
Alessandra Verde, MD, Angelina Grammegna, MD, Emma Petrone, MD, Augusto Mastrominico, MD, Daniele De Brasi, MD, PhD, Claudia Mandato, MD, PhD, Giusy Ranucci, MD, PhD, Maria Simona Sabbatino, MD, PhD, Michelina Sibilio, MD, Paolo Quitadamo, MD
doi : 10.1093/ibd/izab101
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages e112–e113
Azathioprine-induced Myelotoxicity After Switching Mesalazine Compound
Marieke C Barnhoorn, MD, PhD, Bert N Storm, MSc, Nanne K de Boer, MD, PhD, Michael M P J A van der Voorn, MD
doi : 10.1093/ibd/izab102
Inflammatory Bowel Diseases, Volume 27, Issue 9, September 2021, Pages e114–e115
